Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
26.33 USD | -1.75% | +3.70% | +29.96% |
Financials (USD)
Sales 2024 * | 6.35M | Sales 2025 * | 7.38M | Capitalization | 1.37B |
---|---|---|---|---|---|
Net income 2024 * | -151M | Net income 2025 * | -164M | EV / Sales 2024 * | 140 x |
Net cash position 2024 * | 480M | Net cash position 2025 * | 319M | EV / Sales 2025 * | 143 x |
P/E ratio 2024 * |
-8.45
x | P/E ratio 2025 * |
-8.89
x | Employees | 147 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.46% |
Latest transcript on 4D Molecular Therapeutics, Inc.
1 day | -1.75% | ||
1 week | +10.03% | ||
Current month | +10.03% | ||
1 month | -7.94% | ||
3 months | -6.76% | ||
6 months | +121.45% | ||
Current year | +29.96% |
Managers | Title | Age | Since |
---|---|---|---|
Theresa Janke
FOU | Founder | 49 | 13-09-11 |
David Kirn
FOU | Founder | 62 | 13-09-11 |
Uneek Mehra
DFI | Director of Finance/CFO | 51 | 23-09-11 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Milligan
CHM | Chairman | 63 | 20-07-31 |
Susannah Gray
BRD | Director/Board Member | 63 | 20-06-30 |
Charles Theuer
BRD | Director/Board Member | 60 | 15-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.74% | 0 M€ | -3.76% | ||
0.06% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-08 | 26.33 | -1.75% | 340,037 |
24-05-07 | 26.8 | +0.15% | 334,995 |
24-05-06 | 26.76 | +1.44% | 371,209 |
24-05-03 | 26.38 | 0.00% | 320,319 |
24-05-02 | 26.38 | +3.90% | 456,873 |
Delayed Quote Nasdaq, May 08, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+29.96% | 1.37B | |
+22.56% | 46.4B | |
-1.51% | 41.75B | |
+48.83% | 41.37B | |
-3.42% | 29.71B | |
+10.13% | 26.01B | |
-20.44% | 19.52B | |
+26.45% | 12.43B | |
-0.14% | 12.18B | |
-0.47% | 12.13B |
- Stock Market
- Equities
- FDMT Stock